A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.

@article{Kim2010AMP,
  title={A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.},
  author={Sung-Hwan Kim and Ju Sang Kim and Seok Chan Kim and Young Kyoon Kim and Ji Yong Kang and Hyoung Kyu Yoon and Jeong Sup Song and Se Hoon Lee and Hwa Sik Moon and Jin Woo Kim and Kwan Hyoung Kim and Chi Hong Kim and Byoung Yong Shim and Hoon Kim},
  journal={Lung cancer},
  year={2010},
  volume={68 3},
  pages={446-9}
}
Belotecan (Camtobell, CKD602) is a new camptothecin derivative antitumor agent that belongs to the topoisomerase inhibitors. The aim of this phase II study was to evaluate the efficacy and safety of single agent belotecan in patients with small cell lung cancer (SCLC). Patients with previously untreated extensive stage disease (ED) SCLC were entered into the study. Belotecan was given by daily intravenous infusion at 0.5mg/m(2)/day for 5 consecutive days, every 3 weeks. 62 patients were… CONTINUE READING
8 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…